Biotechnology & Medical Research

Immunomedics announces Orphan Drug designation for Veltuzumab for treatment of Pemphigus

Immunomedics Inc:Says that the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) has granted orphan status for the use of veltuzumab, the company's humanized anti-CD20 antibody, for the treatment of pemphigus.

Friday, 21 Nov 2014 08:30am EST

Neptune Technologies & Bioressources Inc appoints President & CEO

Neptune Technologies & Bioressources Inc:Appoints Jim Hamilton as President and Chief Executive Officer (CEO)of the company and a member of the Board, effective Feb. 2, 2015.

Friday, 21 Nov 2014 08:00am EST

Proteo Inc and Proteo Biotech AG announces final analysis of phase II clinical study on Elafin in Coronary Artery Bypass Surgery Completed

Proteo Inc and Proteo Biotech AG:Announced that NHS Lothian's Edinburgh Heart Centre has completed final analysis of data from the investigator initiated Phase II clinical trial (EMPIRE study) with Proteo's drug candidate Elafin for prevention of myocardial injury after coronary artery bypass...

Friday, 21 Nov 2014 06:30am EST

Novogen Limited announces identification of lead ATM drug candidate

Novogen Limited:Says that it has identified its lead anti-tropomyosin (ATM) drug candidate.Says the final selection was confirmed with the company confident that it has developed a major new initiative in the field of chemotherapy.Says the main clinical application of ATM-3507 is believed to lie in...

Thursday, 20 Nov 2014 10:00pm EST


  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary

Upcoming Events

No related earnings announcements are currently scheduled within the next 7 days.

Analyst Research

Report Title Price
Provider: Thomson Reuters StreetEvents
Provider: Edison Investment Research
Provider: Edison Investment Research
Provider: Edison Investment Research
Provider: Edison Investment Research

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.